Starting Materials. S-2-(2-oxopyrrolidin-1-yl)butanamide (Levetiracetam) (S-1) was purchased from Xiamen Top Health Biochem. Tech. Co., Ltd. S-Mandelic acid (S-2), R-mandelic acid (R-2), D-tartaric acid (S-3), and L-tartaric acid (R-3) were purchased from Acros Organics. (RS)-2-(2-oxopyrrolidin-1yl)butanamide (RS-1) was prepared from S-2-(2-oxopyrrolidin-1-yl)butanamide. 10g of S-2-(2oxopyrrolidin-1-yl)butanamide together with catalytic amount (0.05 eq) of MeONa were added to 10 ml of MeOH. The solution was kept at reflux under continuous stirring for 24h, and then cooled to room temperature. The compound crystallizes spontaneously. After filtration, the compound was washed twice with MeOH. The recovered compound was used as such.X-ray Powder Diffraction (XRPD). X-ray diffraction (XRD) measurements were performed with a Siemens D5000 difractometer equipped with a Cu X-ray source operating at 40kV and 40 mA and a secondary monochromater allowing to select the Kα radiation of Cu (λ = 1.5418 Å). A scanning range of 2θ values from 2° to 72° at a scan rate of 0.6° min -1 was applied.Differential Scanning Calorimetry (DSC). DSC measurements were performed on a DSC 821 Mettler Toledo. Prior to measurements, the DSC was calibrated using indium. Perforated aluminium crucibles were used for analysis. The heating rate was either 10 or 5°C min -1 over a range from 25°C to 140°C (alternatively to 180 °C if melting did not yet occur).High-performance liquid chromatography (HPLC). A reverse HPLC system Waters Alliance 2695 equipped with a PDA detector (Waters 2998) turned to 210 nm was used to monitor the Waters Atlantis T3 analytical column (50 mm x 4.6 mm x 3.5 µm). The injection volume was 10 µl and column temperature was keep at 35°C. A chiral HPLC system Waters 600 equipped with a PDA detector (Waters 996) set to 205 nm for detection. A Daicel Chiralpak IA analytical column (250 mm x 4.6 mm x 5 µm) has been used. An isocratic flow rate of 1 ml/min (80% Isohexane, 20% Ethanol) was used for elution. The injection volume was 25 µl and column temperature was keep at 20°C. In both systems, the columns are equilibrated in the initial conditions (for 10 min for reverse HPLC and for 30 min for chiral HPLC).Screening Experiment. The screening procedure consists in preparing a set of vials with given compositions of RS-1, S-1, and S-2. The screening is limited to the right part of the ternary phase diagram (the white part in Figure 2) because of a lack R-1. As R-1 shows no biological interest, this molecule is not marketed. A fixed molar percentage (89 mol%) of acetonitrile is added in each vial, which are then hermetically sealed. Vials are heated up to 60°C until complete dissolution. Vials were then stored at a given temperature and seeded with all of the possible solid states, i.e., RS-1 form I, S-1, S-2, and LSMA co-crystal. After two weeks, the system is assumed to have reached equilibrium.